Warby Parker (WRBY) Non-Current Deffered Revenue (2020 - 2021)
Warby Parker's (WRBY) quarterly Non-Current Deffered Revenue came in at $36.5 million in Q4 2021, up 30.53% YoY from $28.0 million in Q4 2020, and up 17.97% on a QoQ basis from $31.0 million in Q3 2021.
Warby Parker (WRBY) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
Warby Parker (WRBY) has 2 years of Non-Current Deffered Revenue data on file, last reported at $36.5 million in Q4 2021.
- Quarterly Non-Current Deffered Revenue rose 30.53% year-over-year to $36.5 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $36.5 million (up 30.53% YoY) and the FY2021 annual result came in at $36.5 million, up 30.53% from the prior year.
- Non-Current Deffered Revenue advanced to $36.5 million in Q4 2021, from $31.0 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $36.5 million in Q4 2021 to a low of $28.0 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | - |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | - |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | - |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 170.95 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | - |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 13.90 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | - |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 208.80 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | - |
| 10 | Warby Parker | 3.41 Bn | 3.12 Bn | 136.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 36.54 Mn |
| Sep 30, 2021 | 30.98 Mn |
| Dec 31, 2020 | 28.00 Mn |